Similar articles

• Combination of conventional biomarkers for risk stratification in chronic heart failure.

  Niizeki T, Takeishi Y, Kitahara T, Suzuki S, Sasaki T, Ishino M, Kubota I. Niizeki T, et al. J Cardiol. 2009 Apr;53(2):179-87. doi: 10.1016/j.jjcc.2008.10.003. Epub 2008 Dec 4. J Cardiol. 2009. PMID: 19304120
• Biomarkers for chronic heart failure.

  Lainscak M, von Haehling S, Springer J, Anker SD. Lainscak M, et al. Heart Fail Monit. 2007;5(3):77-82. Heart Fail Monit. 2007. PMID: 17487296 Review.
• Natriuretic peptides and other biomarkers in chronic heart failure: from BNP, NT-proBNP, and MR-proANP to routine biochemical markers.

  Lainscak M, von Haehling S, Anker SD. Lainscak M, et al. Int J Cardiol. 2009 Mar 6;132(3):303-11. doi: 10.1016/j.ijcard.2008.11.149. Epub 2009 Jan 13. Int J Cardiol. 2009. PMID: 19144431
• Natriuretic peptide testing for heart failure therapy guidance in the inpatient and outpatient setting.

  Green SM, Green JA, Januzzi JL Jr. Green SM, et al. Am J Ther. 2009 Mar-Apr;16(2):171-7. doi: 10.1097/MJT.0b013e318172797f. Am J Ther. 2009. PMID: 19300043 Review.
• [Natriuretic peptides in patients with heart failure].

  Horii M, Saito Y. Horii M, et al. Nihon Rinsho. 2004 Sep;62 Suppl 9:84-7. Nihon Rinsho. 2004. PMID: 15506343 Review. Japanese. No abstract available.